Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for $10.50 per share in cash, plus a contingent value right (CVR) of up to $3 per share, valuing the deal at a potential $1.3 billion; VERV shares rallied 76% on the news. The acquisition provides Lilly with Verve's gene-editing therapies targeting heart disease, including VERVE-102, which has shown promising early-stage results in reducing cholesterol levels. This move aligns with Lilly's strategic diversification into new therapeutic areas beyond obesity and diabetes, as the company continues to pursue selective M&A deals.

Analysis

Eli Lilly (LLY) has entered a definitive agreement to acquire Verve Therapeutics (VERV) for $10.50 per share in cash, supplemented by a non-tradable contingent value right (CVR) of up to $3 per share, bringing the total potential deal value to approximately $1.3 billion. This CVR is contingent on the first patient being dosed with Verve’s lead asset, VERVE-102, for atherosclerotic cardiovascular disease (ASCVD) in a late-stage study within ten years of the deal's closing. The acquisition, which builds upon an existing partnership where Lilly held opt-in rights for VERVE-102, significantly deepens Lilly's cardiology focus by incorporating Verve's gene-editing pipeline. Key assets include VERVE-102, an investigational in vivo gene-editing therapy targeting cholesterol reduction, which demonstrated encouraging early-stage results with dose-dependent reductions in blood PCSK9 protein and LDL-C levels and has received FDA Fast Track designation. Verve is also advancing VERVE-201, targeting the ANGPTL3 protein, with an early-stage study update anticipated by year-end. Following the news, VERV shares rallied 76% in pre-market trading; year-to-date, the stock has gained 9%, compared to the industry’s 2% growth. This transaction represents Lilly's third targeted M&A deal this year, after a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug and a $1 billion deal for SiteOne Therapeutics' neuroscience assets, reflecting Lilly's strategic intent to diversify beyond its highly successful GLP-1 drugs (Mounjaro and Zepbound) and into other therapeutic areas like immunology, oncology, and neuroscience. The deal, supported by Verve insiders representing nearly 18% of outstanding stock, is expected to close in the third quarter, subject to customary conditions and regulatory clearance. This acquisition occurs within a context of continued M&A activity in the pharmaceutical sector, such as Sanofi's $9.5 billion acquisition of Blueprint Medicines and Bristol Myers' co-development agreement with BioNTech, underscoring Big Pharma's ongoing pursuit of innovative assets despite broader macroeconomic concerns cited for 2025.

Key Decisions for Investors

• Verve Therapeutics (VERV) shareholders should recognize that the $10.50 per share cash offer, which prompted a 76% pre-market rally, likely captures the majority of the immediate value, with potential further upside hinging on the successful achievement of the VERVE-102 late-stage dosing milestone for the CVR payout.
• For Eli Lilly (LLY) investors, this acquisition is a strategically sound move to bolster its pipeline with innovative gene-editing technology in cardiology, aligning with its diversification efforts, though the immediate financial impact on Lilly's vast market capitalization will be modest.
• The ongoing M&A activity in the pharma space, highlighted by this deal and others like Sanofi/Blueprint Medicines, suggests that investors should continue to monitor small to mid-cap biotech companies with novel therapeutic platforms and promising clinical data as potential acquisition targets.